No Data
Buy Rating Affirmed for Kura Oncology Amidst Promising Ziftomenib Trials and Strategic Advantages
Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug
Kura Oncology (KURA) said Tuesday it completed the enrollment of 85 patients in the phase 2 segment of the clinical trial for potential leukemia drug Ziftomenib. The study evaluates Ziftomenib's effec
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Tourmaline Bio (TRML)
Express News | Kura Oncology Inc: Topline Data Expected in Early 2025
Express News | Kura Oncology Inc: Completes Enrollment in Registration-Directed Trial of Ziftomenib in Npm1-Mutant Aml
Estimating The Intrinsic Value Of Kura Oncology, Inc. (NASDAQ:KURA)
Key Insights Kura Oncology's estimated fair value is US$19.69 based on 2 Stage Free Cash Flow to Equity Current share price of US$21.07 suggests Kura Oncology is potentially trading close to its fai